Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVERSTEP: Capecitabine vs Endocrine Maintenance in Metastatic Breast Cancer
NCT02597868Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jan 2013
- Primary completion
- Jul 2016
- Countries
- 1
01
Overview
Randomised, open-label trial in breast cancer (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02597868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597868.